2Patel RK, Lea NC, Heneghan MA, et al. prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-chiari syndrome. Gastroenterology,2006,130:2031-2038.
3Hehlmann R, Jahn M, Baumann B, et al. Essential thrombocythemis: clinical characteristics and course of 61 cases. Cancer, 1988,61:2487.
5Barbu IT, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia a statement from the Italian society of hematology, the italian society of experimental hematology and the italian group for bone marrow transplantation. Haematologica,2004,89:215-232.
